Oxford Study Links Novo Nordisk's Ozempic to 48% Lower Dementia Risk, Mental Benefits

Jul 12, 2024, 09:22 AM

A University of Oxford study has linked Novo Nordisk's diabetes drug Ozempic to a 48% lower risk of dementia and reduced cognitive deficits after a year of use. The study, which analyzed medical records from over 100,000 patients, also found that Ozempic users had a 28% lower smoking rate compared to those on older medications. Additionally, Ozempic was associated with lower rates of a range of other mental problems. The findings raise expectations about the potential ancillary benefits of Ozempic, beyond its primary use for diabetes management. Following the release of the study, Novo Nordisk's stock saw a significant rise.